Get the Stockscreener App
0.3378
0.21%
0.0007
Collplant Biotechnologies Ltd stock is traded at $0.3378, with a volume of 25,432.
It is up +0.21% in the last 24 hours and down -20.78% over the past month.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
See More
Previous Close:
$0.3371
Open:
$0.34
24h Volume:
25,432
Relative Volume:
0.28
Market Cap:
$4.87M
Revenue:
$389.00K
Net Income/Loss:
$-13.13M
P/E Ratio:
-0.3272
EPS:
-1.0323
Net Cash Flow:
$-11.90M
1W Performance:
+1.44%
1M Performance:
-20.78%
6M Performance:
-78.35%
1Y Performance:
-77.02%
1-Day Range:
$0.3201
$0.34
1-Week Range:
$0.3201
$0.3714
52-Week Range:
$0.2711
$3.2324
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
Name
Collplant Biotechnologies Ltd
Sector
Industry
Phone
-
Address
-
Compare CLGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLGN
Collplant Biotechnologies Ltd
|
0.3378 | 4.86M | 389.00K | -13.13M | -11.90M | -1.0323 |
VRTX
Vertex Pharmaceuticals Inc
|
466.79 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.50 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
903.75 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.41 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
165.81 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-23 | Initiated | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd Stock (CLGN) Latest News
Collplant Biotechnologies Ltd (CLGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CLGN Technical Analysis & Stock Price Forecast - Intellectia AI
Collplant Biotechnologies Ltd (CLGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Collplant Biotechnologies Ltd (CLGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Collplant Biotechnologies Ltd (CLGN) Institutional Confidence - TradingKey
Collplant Biotechnologies Ltd (CLGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Collplant Biotechnologies Ltd (CLGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Collplant Biotechnologies Ltd (CLGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Collplant Biotechnologies Ltd (CLGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Collplant Biotechnologies Ltd - TradingKey
CollPlant Heads Toward Nasdaq Deadline With Stock at 40 Cents - Bez Kabli
CollPlant Biotechnologies (CLGN) Holds Near Support Amidst Modest Downside PressureBear Flag - newsline.com
Deal Dispatch: Fertitta Entertainment Buys Caesars For $17.6 Billion, Arsenal Capital Buys Velcro Brands, Teaneck Surgical Center Bankruptcy - Sahm
CollPlant Biotechnologies Posts Wider Q1 Loss as It Explores Strategic Alternatives and Advances Regenerative Aesthetics Pipeline - The Globe and Mail
CollPlant Biotechnologies (CLGN) Hovers Near Support at $0.38 After Marginal DeclineTrend Continuation Trade - The Legal Advocate
Deal Dispatch: Fertitta Entertainment Buys Caesars For $17.6 Billion, Arsenal Capital Buys Velcro Brands, Teaneck Surgical Center Bankruptcy - Benzinga
CollPlant (CLGN) Reports Q1 2026 Financials and Strategic Updates - GuruFocus
CollPlant Q1 revenue falls to $73K, initiates strategic review - grafa.com
Collplant Biotechnologies: No Definitive Timetable for Process >CLGN - Moomoo
Collplant Biotechnologies: Initiates Process to Evaluate Strategic Alternatives Aimed at Maximizing Shareholder Value >CLGN - Moomoo
Collplant Biotechnologies 1Q Loss $3.1M >CLGN - Moomoo
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - PR Newswire
CollPlant Biotechnologies (CLGN) Slips Slightly as Stock Tests Key Support near $0.40ATR Stop - lwvtexas.org
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Quantisnow
CLGN Q4 2025 Earnings: Miss on EPS as Pre-Revenue Biotech Advances PipelineViral Trade Signals - Newser
CLGN Q1'26 Earnings: revenue estimate is 460.00K USD - TradingView
TradingKey - TradingKey
D. Boral Capital Maintains CollPlant Biotechnologies (CLGN) Buy Recommendation - MSN
CLGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Hugh M. Evans (CLGN) details CollPlant share, RSU and option holdings - Stock Titan
[EFFECT] CollPlant Biotechnologies Ltd SEC Filing - Stock Titan
CollPlant (CLGN) registers 3.296M shares for resale; warrants convertible into shares - Stock Titan
CollPlant (CLGN) Stock: Investment Potential Insight (Climbs) 2026-04-20Social Buzz Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Jasmine Seror Net Worth (2026) - GuruFocus
Avraham Havron Net Worth (2026) - GuruFocus
Elan Penn Net Worth (2026) - GuruFocus
Bowman Bagley Net Worth (2026) - GuruFocus
Bar Berta Abelis Net Worth (2026) - GuruFocus
Eran Rotem Net Worth (2026) - GuruFocus
Oren Fahimipoor Net Worth (2026) - GuruFocus
Philippe Bensimon Net Worth (2026) - GuruFocus
Yehiel Tal Net Worth (2026) - GuruFocus
CollPlant (NASDAQ: CLGN) registers 3.296M resale shares; warrants detail - Stock Titan
CLGN SEC FilingsCollplant Biotechnologies Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Momentum Shift: Can CollPlant Biotechnologies Ltd sustain earnings growthGap Up & Trade Opportunity Analysis Reports - baoquankhu1.vn
CollPlant implementing cost-reduction and workforce optimization plan - TipRanks
CLGN Implements Major Cost-Cutting Measures for Future Growth - GuruFocus
CollPlant Ends AbbVie Partnership, Eyes New Opportunities Ahead - Intellectia AI
CollPlant Resets Strategy After AbbVie Ends Filler Deal, Slashes Workforce by 50% - TipRanks
CollPlant ends AbbVie deal, cuts workforce by 50% By Investing.com - Investing.com South Africa
Collplant Biotechnologies Ltd Stock (CLGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):